Startup licenses Purdue syringe design that could improve administration of concentrated dosages of insulin
November 30, 2015
WEST LAFAYETTE, Ind., and INDIANAPOLIS - The founder of a medical device startup based on a Purdue University innovation says his company could help people in the advanced stages of diabetes, which affects more than 9 percent of the population in the United States, according to the Centers for Disease Control and Prevention.
Kyle Hultgren, founder of Imagine Medical Device Inc., said diabetic patients who use more than 200 units of insulin each day often require concentrated dosages. He said patients who need such dosages face several challenges.
"Traditional syringes are not specifically designed to safely accommodate the dosing and administration of this drug. No syringe accurately shows the dose that has been drawn in, which requires users to compute the size of a dose in their head," he said. "Also, early complications of advanced diabetes can include blurry vision or vision loss and losing sensation in the fingers. These complications make it difficult for patients to use small insulin syringes that are currently available."
Purdue University researchers have developed a design for insulin syringes that has a 200 percent larger diameter than traditional syringes and a larger surface area for printing dose markers. Imagine Medical Device has licensed the innovation through the Purdue Research Foundation Office of Technology Commercialization. More than 20 startups based on Purdue intellectual property were launched in the 2015 fiscal year. A video about Imagine Medical Device is available at https://youtu.be/1wNmyr_a8DE.
Kyle Hultgren, founder of Imagine Medical Device Inc., is commercializing a Purdue University-designed syringe for concentrated dosages of insulin. The design has a 200 percent larger diameter than traditional syringes and a larger surface area for printing dose markers. (Purdue Research Foundation photo)
"This new design's shape, size and labeling are not used in currently available syringes for patients," said Hultgren, who also is director of the Purdue University College of Pharmacy's Center for Medication Safety Advancement. "The combination will help patients affected by visual impairments and lower dexterity. The differences also will help users immediately differentiate doses of concentrated insulin from all other forms, which could ensure the safe and accurate administration of this medication."
Hultgren said there are no syringes on the market that accomplish what Imagine Medical Device's syringe can.
"Patients must use tuberculin syringes or other types of delivery device that were not originally intended to administer concentrated insulin, which means the markings are incorrect, small and difficult to read," he said. "If the markings are misinterpreted, the patients are at risk of a profound overdose or underdose of insulin and the consequences of each case could be catastrophic."
Hultgren said Imagine Medical Device is pursuing a filing with the U.S. Food and Drug Administration and other worldwide regulatory authorities.
"We also are looking for partnerships with global medical device suppliers as well as strategic funding partnerships," he said.
For information on other Purdue intellectual property ready for licensing and commercialization, visit http://www.otc-prf.org. For more information about available leadership positions, investing in a Purdue startup or licensing a Purdue innovation, visit http://www.purduefoundry.com.
About Imagine Medical Device Inc.
Imagine Medical Device was founded with the simple mission of advancing the safe administration of high-risk medications. We concentrate our efforts on developing and producing devices that are easier to use and dramatically limit the opportunity for accidental harm associated with medication use. Our cornerstone product is a novel insulin syringe design for accurately delivering doses of concentrated insulin products.
About Purdue Research Foundation Office of Technology Commercialization
The Purdue Research Foundation Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university's academic activities. The office is managed by the Purdue Research Foundation, which received the 2014 Incubator Network of the Year from the National Business Incubation Association for its work in entrepreneurship. For more information about funding and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at email@example.com. For more information on licensing a Purdue innovation, contact the Office of Technology Commercialization at firstname.lastname@example.org.
Purdue Research Foundation contact: Steve Martin, 765-588-3342, email@example.com
Source: Kyle Hultgren, firstname.lastname@example.org